Arginine enzymatic deprivation and diet restriction for cancer treatment

Authors

  • Wissam Zam Al-Andalus University for Medical Sciences; Faculty of Pharmacy, Analytical and Food Chemistry

DOI:

https://doi.org/10.1590/s2175-97902017000300200

Keywords:

Arginine-depleting enzyme/antineoplastic therapy, Dietary deprivation

Abstract

Recent findings in amino acid metabolism and the differences between normal, healthy cells and neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary protein intake, body protein breakdown, or endogenous de novo arginine production and several studies have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different chemo- and radio-therapeutic approaches to be co-applied.

Downloads

Download data is not yet available.

Downloads

Published

2017-01-01

Issue

Section

Reviews

How to Cite

Arginine enzymatic deprivation and diet restriction for cancer treatment. (2017). Brazilian Journal of Pharmaceutical Sciences, 53(3), e00200-. https://doi.org/10.1590/s2175-97902017000300200